COVID-19 Vaccine Boosters in Patients With CKD

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 273 participants.

Also called NCT05022329

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 273 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05022329
Main results
  • BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients Clinical journal of the American Society of Nephrology : CJASN, 2024-01-01 DOI, PubMed 37847518, PMC10843183 PubMed links an erratum for this paper. Erratum: PMID 39392694 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05022329. Randomized; triple masking; primary purpose prevention. Start 2021-09-30 (actual); primary completion 2022-05-11 (actual). Results posted on 2025-02-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
COVID-19 Vaccine Boosters in Patients With CKD
Acronym
BOOST KIDNEY
Condition
Chronic Kidney Diseases
Condition
COVID-19
Intervention (Biological)
Pfizer-BioNTech COVID-19 Vaccine
Intervention (Biological)
MODERNA SARS-CoV-2 Vaccine
Lead sponsor
Sunnybrook Health Sciences Centre (class: other)
Collaborator
University Health Network, Toronto (class: other)
Collaborator
Unity Health Toronto (class: other)
Collaborator
Scarborough General Hospital (class: other)
Collaborator
Providence Healthcare (class: other)

Record details

Record id
cardio:ct-nct05022329
Content hash
47629be5f1770f1530b5b05f2ee08026d5ad2794bb7f035210ffe95a26550ec0